Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
Completed
Boehringer Ingelheim
Phase 4
2005-09-01
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg /
hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg
[Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
Completed
Novartis
Phase 4
2004-11-01
The metabolic syndrome is a classification for patients with a constellation of risk factors
which may include abdominal obesity, hypertension, elevated blood lipids and sugar. Three or
more of these factors together constitute the metabolic syndrome and place these patients at
a greater risk for the development of diabetes and cardiovascular diseases. The purpose of
this study is to determine whether two common drugs to lower blood pressure, whether used
separately or in combination, have different effects on blood sugar levels in patients
diagnosed with the metabolic syndrome.
Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone
Completed
Novartis
Phase 3
2004-09-01
This study will test the effectiveness and safety of a combination treatment in patients
whose blood pressure is not controlled with a single medication.
VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
Completed
Novartis
Phase 3
2004-12-01
To evaluate the efficacy of valsartan 160 mg/HCTZ 25 mg in patients not adequately responding
to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan
medoxomil 20 mg plus HCTZ 12.5 mg by testing the hypothesis that valsartan 160 mg/HCTZ 25 mg
significantly reduces the trough mean sitting diastolic blood pressure (MSDBP) after a 4-week
treatment in the nonresponder population.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
